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Background and Objective: Inhaled corticosteroids (ICS) for COPD has been much
debated. Our aim was to identify characteristics associated with prescribing ICS for patients
with COPD alone compared to those with concomitant asthma in general practice.
Patients and Methods: Participating general practitioners (GPs) (n=144) recruited patients
with COPD (ICPC 2nd ed. code R95) currently prescribed ICS (ACT code R03AK and
R03BA). Data, if available, on demographics, smoking habits, spirometry, COPD medica-
tion, dyspnea score, and exacerbation history were retrieved from the medical records.
Logistic regression analysis was used to identify possible differences in characteristics
between patients with COPD alone compared to those having a concomitant diagnosis of
asthma.
Results: A total of 2.289 (45% males) COPD patients on ICS were recruited. Compared to
patients with COPD alone (n=1.749), those with COPD and concomitant asthma (n=540)
were younger (p<0.001), had higher BMI, higher FEV1/FVC ratio, higher blood eosinophil
count and less life-time tobacco exposure (36 and 26 pack-years, respectively). Compared to
COPD alone, logistic regression analysis showed that COPD with concomitant asthma was
significantly associated to age (OR 0.94; CI 0.92 to 0.97; p<0.001), pack-years of smoking
(OR 0.98; CI 0.97 to 0.99; p<0.001), FEV1%pred (OR 1.02; CI 1.00 to 1.03; p=0.005), and
doctor-diagnosed depression (OR 2.59; CI 1.20 to 5.58; p=0.015).
Conclusion: In COPD patients currently prescribed ICS, the presence of concomitant asthma
was associated with being younger, having less tobacco exposure, more preserved lung function
and a higher likelihood of doctor-diagnosed depression compared to COPD alone.
Keywords: COPD, concomitant asthma, inhaled corticosteroids (ICS), general practice
Introduction
Long-acting bronchodilators are the cornerstone of pharmacological treatment of
chronic obstructive pulmonary disease (COPD).1 However, inhaled corticosteroids
(ICS) have been shown to reduce exacerbations, hospitalizations and have also been
linked to a reduction in mortality in COPD patients.2–5 Global Initiative of Chronic
Obstructive Lung Disease (GOLD) has recommended using ICS in patients with
severe airflow limitation and/or patients at high risk of COPD exacerbations.1
However, there is evidence of widespread use of ICS in patients with less severe
COPD not fulfilling the GOLD criteria for ICS use.6–8
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A meta-analysis of available clinical trials suggested that
ICS treatment in patients with COPD may reduce the annual
decline in lung function.2 Furthermore, improvements in
health status has been demonstrated in COPD patients pre-
scribed monotherapy with LABA or LAMA,9,10 but add-on
ICS to long-acting bronchodilator treatment has been demon-
strated to improve health status even further.11
ICS-therapy may be associated with potentially severe
side effects as studies have demonstrated an increased risk
of fractures and pneumonia.12–14 Furthermore, the distinc-
tion between side effects such as pneumonia and symp-
toms is difficult to define in a primary care setting.15 The
adverse effects of ICS treatment in COPD patients points
to the importance of more research on the risk-benefit
profile of ICS.16,17 It is therefore crucial to understand
what determines the use of ICS in COPD patients.
In recent years there has been an increasing interest in
understanding the concomitant diagnosis of asthma in
COPD patients and distinguishing clinical features asso-
ciated with either COPD or asthma in patients presenting
with obstructive lung diseases.18,19 This has given rise to
treatment recommendations for COPD patients with con-
comitant asthma.20 However, there is no consensus on
a definition of COPD patients with a concomitant asthma
diagnosis, and it has proven challenging to properly char-
acterize these patients. In a large cohort of patients with
COPD managed in primary care and currently prescribed
inhaled corticosteroids, our aim was to identify possible
differences in characteristics associated with prescribing
ICS for patients diagnosed with COPD alone and those
with concomitant asthma.
Patients and Methods
All study participants had a confirmed diagnosis of COPD,
were currently prescribed ICS (coded as International
Classification of Primary Care, 2nd ed. code R95 in electro-
nic patient journals and with the ACT code R03AK and
R03BA, indicating ICS treatment), and were managed by
general practitioners (GPs) in primary care, and for some
patients, also specialists. The selection process of patients
participating in the study is summarized in Figure 1, also
illustrating the primary focus of the present study. Further
details related to the selection procedure has been published
previously.21 Participating GPs provided information, if
available, on demographics, clinical characteristics, blood
eosinophils, consultations for respiratory disease, prescribed
medication, hospital admissions for COPD, previous COPD
exacerbations, smoking status, selected comorbidities, and
duration of COPD for all recruited patients. Each general
practice included up to a maximum of 20 randomly selected
patients. All patients were assigned a unique project ID
number to assure anonymity with only the designated GP
being unblinded to patient identity.
The study was approved by the Danish Data Protection
Agency. The present study was a non-interventional, non-
drug study, and, therefore, it was not mandatory to obtain
approval from the ethical committee and the Danish
Medicines Agency.
Assessment of Symptoms, Airflow
Limitation and Acute Exacerbations
Severity of symptoms was assessed by the Medical Research
Council (MRC) scale22 and/or the COPD assessment test
(CAT). Spirometric findings were used to estimate airflow
obstruction and categorize the severity of the disease, based
on a cut-off for FEV1according to the classification provided
by GOLD.23 Patients were also classified into four groups, i.e.,
A, B, C and D, according to the GOLD 2017 classification,
based on COPD symptoms (MRC-scale score  2 and/or
CAT score  10) and the exacerbation history.
Data Analysis
Data are reported as mean values ± one standard deviation
(SD). Clinical variables and characteristics of COPD alone
were compared to COPD with concomitant asthma using
independent sample t-test for continuous variables. The
comparison between COPD alone and COPD patients
with a concomitant asthma diagnosis in terms of possible
clinically-relevant variables and characteristics was con-
ducted using a multinomial logistic regression model and
reported as odds ratios and 95% confidence intervals.
A p-value <0.05 was considered statistically significant.
Data were analyzed using the statistical program IBM
SPSS version 25 (IBM Corporation, Armonk, NY, USA).
Results
Characteristics of Enrolled Patients with
COPD
Of the COPD patients currently on ICS therapy (n=2289)
included in the present study, 540 (24%) were classified by
the GP as having concomitant asthma.
Slightly more female than male patients were recruited
(55% vs. 45%), whereas no difference was found in mean
age between sexes (71 years; p=0.83). Further character-
istics of the patients are given in Table 1.
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COPD Alone and COPD Patients with
a Concomitant Asthma Diagnosis
Baseline characteristics of the two groups, i.e., COPD alone
and COPDwith concomitant asthma, are outlined in Table 2.
A statistically significant difference was found in meanMRC
for COPD alone and for COPD patients with concomitant
asthma (p<0.001). The mean number of pack years for
COPD alone patients and for COPD patients with concomi-
tant asthma, respectively, was 36 and 26 (p<0.001). COPD
patients with concomitant asthma had higher blood-
eosinophil count than patients with COPD alone (p=0.02).
Further details are given in Table 2.
The distribution of severity of airflow limitation, based on
the GOLD classification, among patients with COPD alone
and COPD with concomitant asthma is presented in Figure 2,
revealing a significant difference between the two groups
(p<0.001). The distribution of themost common comorbidities
and levels of blood eosinophils, respectively, in patients with
COPD alone and COPD with concomitant asthma are pre-
sented in Figure 3 and Table 3.
Compared to COPD alone, logistic regression analysis
showed that COPD with concomitant asthma was signifi-
cantly associated to age (OR 0.94; CI 0.92 to 0.97;
p<0.001), pack-years of smoking (OR 0.98; CI 0.97 to
0.99; p<0.001), FEV1%pred (OR 1.02; CI 1.00 to 1.03;
p=0.005), and doctor-diagnosed depression (OR 2.59; CI
1.20 to 5.58; p=0.015) (Table 4).
Discussion
This study shows that a concomitant asthma diagnosis in
COPD patients treated with ICS in primary care is asso-
ciated with younger age, less airflow limitation, but more
likely to be associated with a doctor-diagnosis of depres-
sion compared to patients with COPD alone.
Reduced benefit from corticosteroids and increased
inflammation in the airways has previously been suggested
as a side effect of being a current smoker in patients with
chronic airway diseases such as COPD and asthma.24 On
the other hand, a recent study analyzing data from three
randomized controlled trials of budesonide-formoterol
A total of 416.233 patients 
registered in 138 general practices
Patients with a COPD diagnosis (3% of all patients)
AND 
Prescribed inhaled corticosteroid (ICS)
(31.6% of COPD patients)
Excluded patients (n = 304):
Reassortment revealed patients not 
meeting both inclusion criteria.
Final cohort (n = 2289). 
COPD with concomitant asthma 
(n = 540) 
AND
COPD alone (n = 1749)
Figure 1 Selection process of patients with chronic obstructive pulmonary disease (COPD) alone and COPD with concomitant asthma, recruited from general practice and
currently prescribed inhaled corticosteroids (ICS).
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studies in COPD patients concluded that currently smok-
ing COPD patients on ICS/LABA therapy had reduced
exacerbation rates compared to those on LABA alone
treatment at greater blood-eosinophil counts.25 In line
with this, the present study found that COPD patients
with concomitant asthma and on average higher mean
blood eosinophil count had a lower exacerbation rate
compared to patients with COPD alone and a lower
blood eosinophil count indicating that ICS is more bene-
ficial in the COPD with concomitant asthma group of
patients. COPD patients with concomitant asthma also
had higher lung function, however, this might be due to
the fewer pack-years smoked.
A quarter of a cohort of COPD patients have asthma
characteristics and according to the strategy document by
GOLD might be eligible for ICS treatment.20 In keeping
with these facts, the respective GPs in this study have
rightfully continued ICS prescription because of concomi-
tant asthma in a quarter of included patients. Continued
ICS prescription might also depend on whether patients
presented with airflow limitation and/or severe symptoms,
although these predictors alone should not determine ICS
prescription according to the strategy document by
GOLD.20
In this study, classification of participants to have COPD
with concomitant asthma was based on the participating
GPs interpretation of the overall case history, objective
findings and response to therapy. As this was a non-
interventional study, no formal criteria for a concomitant
diagnosis of asthma was applied, which may be the back-
ground for the observation that the proportion of COPD
patients in the present study with a concomitant diagnosis of
asthma was a little higher compared to what has been
reported from other studies. However, on the other hand,
all patients in the present study were currently prescribed
ICS and by that, it may be expected to observe a slightly
higher proportion of patients classified as having concomi-
tant asthma.
Similar to the present study, other studies have pre-
viously found higher prevalence of depressive symptoms
among patients with chronic airway disease such as
asthma.26,27 Another study also found prevalence of
depression to be greater among patients with uncontrolled
asthma compared to those with well-controlled asthma,
suggesting that treatment is crucial in depression preva-
lence in chronic airway disease.28 In addition, another
recent study found that the risk of depression is higher in
patients presenting with symptoms of both asthma and
COPD.29
Our study has strengths worth mentioning. First, we
included a large cohort based on a real-world population of
COPD patients followed by their designated GPs. This
reflects information gathered by day-to-day clinical visits
of patients in general practices and follow-up by GPs,
including information on hospital admissions and respira-
tory outpatient visits. Additionally, plenty of data was
available from this large population-based cohort, which
at first sight makes it exceptionally relevant in finding
Table 1 Characteristics of Enrolled Patients (n=2289) with Chronic
Obstructive Pulmonary Disease (COPD) Managed in Primary Care
andCurrently Prescribed Inhaled Corticosteroids (ICS) According to
Sex
Males
(n=1024)
Females
(n=1265)
Age (years) 71.06 (SD 10.84) 70.96 (SD 10.79)
BMI (kg/m2) 27.53 (SD 5.47) 26.57 (SD 6.86)
Pack-years (n) 36.62 (SD 22.71) 30.21 (SD 21.55)
FEV1=FVC 0.56 (SD 0.15) 0.59 (SD 0.14)
FEV1%predicted (%) 57.38 (SD 22.89) 62.50 (SD 23.63)
FEV1(L) 1.74 (SD 0.73) 1.32 (SD 0.53)
Abbreviations: BMI, body mass index; FEV1 , forced expiratory volume in
1 second; FVC, forced vital capacity.
Table 2 Baseline Characteristics of Enrolled Patients (n=2289)
with Chronic Obstructive Pulmonary Disease (COPD) Managed
in Primary Care and Currently Prescribed Inhaled Corticosteroids
(ICS) Divided by Whether Patients Have a Concomitant Diagnosis
of Asthma (n=540) or COPDAlone (n=1749)
COPD with
Concomitant
Asthma
(n=540)
COPD Alone
(n=1749)
Age (years), mean 69.35 (SD 11.99) 72.83 (SD 10.28)*
BMI (kg/m2), mean 28.10 (SD 6.47) 26.68 (SD 6.21)*
Pack-years (n), mean 25.75 (SD 20.97) 35.52 (SD 22.21)*
FEV1=FVC, mean 0.62 (SD 0.14) 0.56 (SD 0.15)*
FEV1%predicted (%), mean 68.89 (SD 22.33) 57.47 (SD 23.11)*
FEV1(L), mean 1.75 (SD 0.68) 1.43 (SD 0.64)*
B-eosinophils (109/L), mean 0.27 (SD 0.23) 0.24 (SD 0.20)**
MRC-score (n=1163), mean 2.35 (SD 0.98) 2.79 (SD 1.13)*
CAT-score (n=54), mean 14.75 (SD 8.42) 17.56 (SD 7.54)
Annual exacerbation, mean 0.66 (SD 1.15) 0.95 (SD 1.64)*
Notes: CAT, COPD assessment test. For the comparison between COPD with
concomitant asthma and COPD alone: *p<0.001; **p<0.05.
Abbreviations: BMI, body mass index; FEV1 , forced expiratory volume in
1 second; FVC, forced vital capacity; B-eosinophils, blood eosinophils; MRC, med-
ical research council.
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different significances among different subsets of included
COPD patients.
Certain limitations should be emphasized in the current
study. The results presented here might resemble random
significant associations between clinical variables and
characteristics in subpopulations of COPD patients treated
with ICS in primary care. We found a significant associa-
tion between depression and concomitant asthma, which
has also been reported in previous studies of the so-called
asthma-COPD overlap. As shown in Table 4, the confi-
dence interval for the association was wide, but based on
previous findings, also in patient with more severe asthma,
the overserved association in the present study is likely to
be valid.
On the other hand, some of the significant associations
found in this study might have been influenced by
a possible lack of a thorough examination and diagnosis
of COPD patients in general practice leading to less clin-
ical important differences and findings between patients
with COPD alone and COPD with concomitant asthma. In
line with this, patients with COPD alone may have
a history with more exacerbations primarily due to having
more severe disease (Figure 2). Lastly, very few patients
had information on CAT-score (2.4%), which might have
0
5
10
15
20
25
30
35
COPD alone COPD with concomitant asthma
%
Cardiovascular disease Type two diabetes Osteoporosis Depression Anxiety
Figure 3 Comorbidities in patients with chronic obstructive pulmonary disease (COPD) alone compared to COPD patients with concomitant asthma.
0
5
10
15
20
25
30
COPD alone COPD with concomitant asthma
%
GOLD classification 
I II III IV
Figure 2 Distribution of severity of airflow limitation, defined according to Global Initiative of Obstructive Lung Disease (GOLD), among patients with chronic obstructive
pulmonary disease (COPD) alone and COPD with concomitant asthma.
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made it difficult to demonstrate genuinely significant dif-
ference in symptoms amongst patients with COPD alone
and COPD patients with concomitant asthma. Meanwhile,
almost all patients had information on exacerbation rate
(99.3%) and all had information on whether they had
a concomitant diagnosis of asthma. This reflects
a necessity for further use of symptom scores as part of
the assessment of COPD patients in primary care.
In the current study investigating COPD patients pre-
scribed ICS in primary care, a diagnosis of concomitant
asthma indicated higher risk of depression, less exposure to
tobacco smoke, and greater lung function. These main
differences between patients with COPD alone and COPD
with concomitant asthma indicate the need for investigation
of detailed treatment strategies in primary care COPD patients,
not least for those with concomitant asthma, and hopefully,
reduce risk of unbeneficial ICS treatment in the future.
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